9 research outputs found
MYH9 and APOL1 gene polymorphisms and the risk of CKD in patients with lupus nephritis from an admixture population.
MYH9 polymorphisms have been described to be associated with the risk of CKD in non-diabetic nephropathy, HIV nephropathy and FSGS. Predominating in black descendants, MHY9 genetic variants could partially explain the excess risk of CKD associated with African ancestry. However, recent data suggests that APOL1 gene co-segregate with MYH9, and could be the gene truly associated with CKD risk. In this study, we evaluated the role of MYH9 and APOL1 gene polymorphisms in the risk of CKD in Brazilian patients with lupus nephritis (LN). A retrospective analysis of 196 LN patients was done. MYH9 rs4821480, rs2032487, rs4821481 and rs3752462, APOL 1rs73885319, rs16996616, rs60910145, rs71785313, and APOL3 rs11089781 gene polymorphisms were determined. Genetic ancestry was ascertained both by autossomal ancestry and mitochondrial haplogroup. Primary outcome was defined as doubling of serum creatinine (DC) or end stage renal disease (ESRD). Sixty-two patients presented the PO. In our population, MYH9 and APOL1 were not in LD. None APOL polymorphism was associated with the PO, whereas rs3752462 MYH9 polymorphism showed a positive association (HR3.72, 95%CI 1.47-9.38, p = 0.005). When we analyzed the MYH9 E1 haplotype, the GCCT carriers (1 or 2 alelles present in 29.7% in the PO group vs. 18.5% in controls) showed a significant association to the risk of PO, even after adjustments for baseline estimated creatinine clearance and autossomal ancestry (HR 2.0, 95%CI 1.2-3.4, p = 0.01). Our results show that in our population MYH9, but not APOL1, gene polymorphisms confer an increased risk of CKD in LN patients, independently of race
Baseline clinical, laboratorial and histological data of 196 LN patients and according to renal outcome.
<p>* p = Mann-Whitney or chi-square.</p><p>** 9 patients were excluded because treatment was not performed or interrupted.</p><p>IQR, interquartile range.</p
Unadjusted and adjusted Cox proportional hazard models on the risk of CKD according to rs3752462 MYH9 polymorphism.
<p>* Cox proportional hazard models.</p
Risk of the PO according to MYH9 and APOL gene polymorphisms in 196 LN patients.
<p>* p = chi-square.</p
Cox proportional hazard models and Kaplan-Meier curve of the risk of the PO according to <i>MYH9</i> E1 haplotype.
<p>Cox proportional hazard models and Kaplan-Meier curve of the risk of the PO according to <i>MYH9</i> E1 haplotype.</p
Baseline clinical, laboratorial and histological data according to <i>MYH9</i> E1 haplotype groups.
<p>* p = Mann-Whitney or chi-square.</p><p>** 9 patients were excluded because treatment was not performed or interrupted.</p><p>IQR, interquartile range.</p
Linkage disequilibrium structure of <i>MYH9</i> and <i>APOL1</i> gene polymorphisms in 196 LN Brazilian patients.
<p>Linkage disequilibrium structure of <i>MYH9</i> and <i>APOL1</i> gene polymorphisms in 196 LN Brazilian patients.</p